Skip to main content

Table 2 Women per week by initial treatment within 3 months of diagnosis, diagnosis period, and stage

From: Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study

 

Total

Untreated

BCS

Mx with IBR

Mx without IBR

Chemotherapy

Hormonal treatment

Other

DCIS

        

 2018/2019, wk 2–17

42.8

3.9 (9.1)

27.9 (65.2)

5.0 (11.8)

5.4 (12.6)

0.2 (0.4)

0.4 (0.9)

0.0 (0.2)

 2020, wk 2–8

49.7

8.1 (16.4) ↑

29.7 (59.8)

5.1 (10.3)

6.4 (12.9)

0.1 (0.3)

0.1 (0.3)

0.0 (0.0)

 2020, wk 9–11

41.3

7.3 (17.7) ↑

22.7 (54.8)

3.7 (8.9)

7.0 (16.9)

0.0 (0.0)

0.7 (1.6)

0.0 (0.0)

 2020, wk 12–13

32.0

3.5 (10.9)

19.5 (60.9)a

2.0 (6.3)

5.5 (17.2)

0.0 (0.0)

1.5 (4.7)b

0.0 (0.0)

 2020, wk 14–17

9.8

1.0 (10.3)

4.5 (46.2)

2.0 (20.5)

1.8 (17.9)

0.3 (2.6)

0.3 (2.6)

0.0 (0.0)

Stage I

        

 2018/2019, wk 2–17

147.0

2.7 (1.8)

103.0 (70.1)

10.1 (6.9)

16.8 (11.4)

7.1 (4.8)

7.3 (4.9)

0.2 (0.1)

 2020, wk 2–8

153.1

2.6 (1.7)

104.6 (68.3)

8.9 (5.8)c

18.0 (11.8)

9.1 (6.0)

9.9 (6.4)

0.1 (0.1)

 2020, wk 9–11

138.7

1.7 (1.2)

95.0 (68.5)

10.0 (7.2)

17.7 (12.7)

2.3 (1.7) ↓

12.0 (8.7)d

0.0 (0.0)

 2020, wk 12–13

83.5

1.0 (1.2)

55.5 (66.5)

3.5 (4.2)

9.5 (11.4)

3.0 (3.6)

11.0 (13.2)e

0.0 (0.0)

 2020, wk 14–17

52.5

0.8 (1.4)

29.0 (55.2) ↓

4.8 (9.0)

7.5 (14.3)

5.0 (9.5) ↑

5.5 (10.5) ↑

0.0 (0.0)

Stage II

        

 2018/2019, wk 2–17

119.1

2.6 (2.2)

36.3 (30.5)

5.3 (4.5)

20.9 (17.6)

37.5 (31.5)

16.0 (13.4)

0.4 (0.4)

 2020, wk 2–8

127.1

2.9 (2.2)

35.9 (28.2)

5.9 (4.6)

21.7 (17.1)

38.7 (30.4)

21.9 (17.2)f

0.3 (0.2)

 2020, wk 9–11

105.3

3.3 (3.2)

32.0 (30.4)

3.3 (3.2)

20.0 (19.0)

22.7 (21.5) ↓

24.0 (22.8)d

0.0 (0.0)

 2020, wk 12–13

71.0

1.0 (1.4)

22.5 (31.7)

1.5 (2.1)

10.5 (14.8)

20.0 (28.2)

15.5 (21.8)g

0.0 (0.0)

 2020, wk 14–17

66.0

1.0 (1.5)

17.3 (26.1)

2.0 (3.0)

12.3 (18.6)

22.5 (34.1)

11.0 (16.7)

0.0 (0.0)

Stage III

        

 2018/2019, wk 2–17

32.7

0.8 (2.6)

2.0 (6.2)

0.6 (1.8)

5.9 (18.1)

17.5 (53.6)

5.3 (16.2)

0.5 (1.4)

 2020, wk 2–8

29.9

1.1 (3.8)

2.4 (8.1)

0.4 (1.4)

6.0 (20.1)

14.4 (48.3)

5.4 (18.2)

0.0 (0.0)

 2020, wk 9–11

27.3

0.3 (1.2)

1.3 (4.9)

0.3 (1.2)

5.3 (19.5)

14.0 (51.2)h

6.0 (22.0)

0.0 (0.0)

 2020, wk 12–13

17.5

0.0 (0.0)

0.5 (2.9)

1.5 (8.6) ↑

2.5 (14.3)

6.0 (34.3)

7.0 (40.0)i

0.0 (0.0)

 2020, wk 14–17

15.5

0.3 (1.6)

0.8 (4.8)

1.0 (6.5) ↑

2.3 (14.5)

9.3 (59.7)

2.0 (12.9)

0.0 (0.0)

Stage IV

        

 2018/2019, wk 2–17

17.2

1.6 (9.3)

0.3 (2.0)

0.0 (0.2)

0.6 (3.5)

5.7 (33.3)

7.4 (43.3)

1.5 (8.5)

 2020, wk 2–8

19.1

3.1 (16.4) ↑

0.4 (2.2)

0.0 (0.0)

0.9 (4.5)

6.3 (32.8)

7.4 (38.8)

1.0 (5.2)

 2020, wk 9–11

16.3

2.0 (12.2)

0.7 (4.1)

0.0 (0.0)

0.7 (4.1)

5.3 (32.7)j

7.7 (46.9)

0.0 (0.0)

 2020, wk 12–13

12.0

1.0 (8.3)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

3.5 (29.2)k

7.5 (62.5) ↑

0.0 (0.0)

 2020, wk 14–17

13.5

1.5 (11.1)

0.0 (0.0)

0.0 (0.0)

0.3 (1.9)

5.8 (42.6)l

5.3 (38.9)m

0.8 (5.6)

  1. Data are shown as average n (%). We compared data for weeks 2–17, 2020 (the COVID-19 period) with those for weeks 2–17, 2018/2019 using the Mantel–Haenszel test, adjusted by age (< 40, 40–50, 50–65, 65–74, > 74 years)
  2. The arrows show statistically significant data corrected for age: ↑ = more patients received this therapy; ↓ = fewer patients received this therapy
  3. BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; Mx, mastectomy; wk, week
  4. Analyses stratified per age group was performed and significant differences are explained:
  5. aLower proportion of patients 65–74 years old with DCIS received BCS
  6. bHigher proportion of patients 65–74 years old with DCIS received hormonal treatment
  7. cHigher proportion of patients < 40 years old with stage I received mastectomy with IBR
  8. dHigher proportion of patients 50–74 years old with stage I or stage II received hormonal treatment
  9. eHigher proportion of patients < 75 years old with stage I received hormonal treatment
  10. fHigher proportion of patients 40–74 years old with stage II received hormonal treatment
  11. gHigher proportion of patients < 50 years old or > 74 years old with stage II received hormonal treatment
  12. hHigher proportion of patients < 40 years old with stage III received chemotherapy
  13. iHigher proportion of patients < 50 years old or 65–74 years old with stage III received hormonal treatment
  14. jHigher proportion of patients < 40 years old with stage IV received chemotherapy
  15. kHigher proportion of patients 40–49 years old with stage IV received chemotherapy
  16. lHigher proportion of patients aged < 40 years old or 50–64 years old with stage IV received chemotherapy
  17. mHigher proportion of patients 40–49 years old or 65–74 years old with stage IV received hormonal treatment
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us